News
Future Fertility announces new strategic partnership with Eugin Group Spain
Future Fertility’s Deep Learning model can evaluate each egg’s unique likelihood of developing into a healthy embryo
Future Fertility, the pioneer in AI-powered oocyte quality assessment, has announced a new strategic partnership with Eugin Group’s Spain-based fertility clinics.
Under this agreement, Future Fertility’s MAGENTA™ tool will be validated in the Eugin clinics, and personalised oocyte assessment reports will be commercially available to egg freezing and IVF-ICSI patients at both the Eugin Barcelona and Eugin Madrid locations.
Eugin Group is a leading global network of fertility clinics operating in Europe and Latin America, with a reputation for leadership in scientific research and the use of state-of-the-art technologies to advance patient care.
With headquarters based in Spain, a country renowned for its deep history of advancing fertility research and patient care, Eugin Group’s decision to implement Future Fertility’s technology in its flagship clinics signals increasing industry-wide confidence in their AI-based tools.
Future Fertility’s technology gained significant momentum within the fertility industry in 2023, with an installed base of over 90 clinics across more than 20 countries.
With an ability to seamlessly integrate into all laboratory set-ups, including time-lapse and microscope-only, adoption of their tools has been drastically increasing across the industry, as the dataset has grown to over 120,000 oocyte images and affiliated outcomes. With the broader adoption of these tools, the standard of care for evaluating oocyte quality is also evolving.
Historically, fertility specialists could only provide a general estimate of a patient’s chance of success based on their age and the number of mature eggs retrieved.
Future Fertility’s Deep Learning model can evaluate each egg’s unique likelihood of developing into a healthy embryo based on its image, bringing a new level of personalisation to fertility care.
Mina Popovic, the group’s scientific director comments: “Future Fertility’s AI tools enable our lab teams to assess egg quality in an objective, data-driven way that wasn’t previously possible.
“The Future Fertility team has been diligent in their approach to clinical validation and ensuring their tools are also backed through peer-reviewed scientific research. This gives us confidence that these tools are here to stay, and we’re headed towards a new standard of care in oocyte quality assessment.”
“These personalised insights enable our clinical team to tailor treatment plans to each patient’s needs and provide much-needed clarity for the patient regarding what they can expect to achieve from their treatment, while enabling stronger patient counselling on next steps,” adds Amelia Rodríguez-Aranda, medical director at Eugin Group.
Eugin Group’s decision to expand Future Fertility’s tools to its Spanish clinics follows the successful implementation of this technology in another network clinic in Argentina; CEGYR, a Eugin Group clinic in Buenos Aires, recently became the first clinic globally to use Future Fertility’s oocyte assessment software on every egg freezing and IVF-ICSI cycle.
“Eugin Group is recognised as a global powerhouse in terms of quality of care across the network. We’re excited to see the clinical and scientific use cases for our tools being proven out through such an esteemed partner,” says Christy Prada, CEO of Future Fertility.
“Eugin Group’s decision to expand our partnership to their two major home base clinics really speaks for itself – it’s great to see the value that our oocyte assessment tools are creating within the industry.
“We look forward to working together to evaluate other points along the IVF journey where our tools can help to improve outcomes and the overall patient experience.”
The Femtech World Awards are set to recognise the people, organisations and innovations revolutionising how we treat and diagnose cancer in women.
Now in its third year, the Femtech World Awards celebrates the very best of female-led and focused health innovation, spanning menopause, fertility, cardiovascular disease and beyond.
The Women’s Cancer Innovation award will honour a groundbreaking innovation dedicated to the prevention, early detection treatment or ongoing care of cancers that uniquely or disproportionately affect women.
The winner will have demonstrated exceptional progress in advancing research, technology or patient-centred solutions that improve outcomes and quality of life.
This award celebrates those driving transformative change in the fight against women’s cancers.
The Women’s Cancer Innovation Award is sponsored by Endomag.
Endomag believes everyone deserves a better standard of cancer care – that’s why they design their cancer localisation technologies with both the clinician and patient in mind.
Many leading hospitals across the world use their unique solutions to help breast cancer patients avoid surgery when it isn’t needed, and experience better outcomes when it is.
Their Magseed marker is a tiny, non-radioactive seed, ideal for accurately marking tumours and lymph nodes, while the Magtrace lymphatic tracer is the world’s first, long-lasting, non-radioactive dual tracer for lymphatic mapping.
Paired with the Sentimag localisation platform, they have now been widely proven across over 200 clinical studies, featuring more than 20,000 patients.
This award is one of 10 featuring at the event, which last year attracted entries from across the UK, Europe and North America.
Award winners will receive a trophy and the opportunity to be interviewed by Femtech World.
Both winners and shortlisted entries will receive extensive coverage across all Femtech World platforms.
Find out more and enter for free here.
Two designer perfumes have been recalled over a banned chemical linked to fertility risk and harm to unborn children.
Hello by Lionel Richie and Hot by United Colours of Benetton, both sold by discount chain Savers Health and Beauty, have been recalled in a notice from the Office for Product Safety and Standards.
The products contain butylphenyl methylpropional (BMHCA), also known as lilial, a synthetic floral fragrance classified as toxic to reproductive health.
The chemical, which mimics a lily of the valley scent, was used in many cosmetics and household products until March 2022, when it was banned in the UK and EU.
According to the notice, BMHCA can harm the reproductive system and the health of unborn children, and may cause skin sensitisation.
The Office for Product Safety and Standards said: “Affected products have been recalled by Savers Health and Beauty. Customers should return any of the above products purchased at a Savers store to the place of purchase, where they will be issued a full refund.
“Only products purchased in Savers Health and Beauty stores with the barcodes listed are affected by this recall. If you are unsure if you have one of the above products, please contact Savers Health and Beauty on help@savers.co.uk.”
The initial warning about the items was issued last month, with products recalled from customers on Wednesday.
Savers said in a statement that it would like to apologise for any inconvenience caused.
Affected products include Hello by Lionel Richie Femme and Homme in 30ml, 50ml and 100ml sizes, and Benetton Hot 100ml EDT.
Pregnant women exposed to ‘forever chemicals’ could be at greater risk of developing gestational diabetes, a recent study suggests.
PFAS (per- and polyfluoroalkyl substances) are toxic chemicals that do not break down in the body, leaching from non-stick cookware, waterproof textiles and takeaway containers into food or via skin contact and building up in vital organs.
Researchers analysed 79 animal and human studies evaluating the relationship between PFAS, diabetes and pregnancy.
They found that higher exposure led to consistently higher insulin resistance, where the body’s cells do not respond properly to insulin, and higher rates of gestational diabetes.
The research was conducted at the Icahn School of Medicine at Mount Sinai in New York City.
Dr Sandra India-Aldana, co-first study author, said: “This is the most comprehensive synthesis of evidence to date examining how PFAS exposure relates not only to diabetes risk, but also to the underlying clinical markers that precede disease.
“Our findings suggest that pregnancy may be a particularly sensitive window during which PFAS exposure may increase risk for gestational diabetes.
Gestational diabetes has been rising for the past decade.
In babies, it may lead to high birth weight, preterm labour and increased risk of obesity and type 2 diabetes later in life.
Mothers may also face higher risk of high blood pressure and developing diabetes in future.
Dr Xin Yu, co-first study author, said: “Gestational diabetes has lasting implications for both mother and child.
“This research supports the growing recognition that environmental exposures like PFAS should be part of conversations around preventive care and risk reduction during pregnancy.”
Dr Damaskini Valvi, senior study author, said: “These results are alarming as almost everyone is exposed to PFAS, and gestational diabetes can have severe long-term complications for mothers and their children.
“We need larger longitudinal studies with well-characterised type 1 and type 2 diabetes cases to fully characterise PFAS impacts on diabetes risk and its long-term complications for affected individuals and their families.
“These results underscore the importance of considering PFAS and other hazardous environmental chemical exposures as part of comprehensive clinical risk assessment and preventive care, particularly during pregnancy.”
-
Insight1 day agoDesigner perfumes recalled over banned chemical posing fertility risk
-
Fertility2 weeks ago2025: The year IVF innovation went from lab to life
-
Insight1 week ago‘Rejuvenated’ eggs raise hopes for improved IVF outcomes
-
News4 weeks agoCan biotech help close the fertility gap? Inside the race to improve egg quality
-
Insight4 weeks agoAI-driven digital tool delivers sustained blood pressure reductions, study finds
-
Insight3 days agoHigher maternal blood pressure increases risk of pregnancy complications, study finds
-
Features3 days agoWomen’s health enters a new era – the trends shaping femtech in 2026
-
Features3 days agoBest menopause apps and products for 2026